High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase
Background: Schizophrenia is a chronic mental disorder, characterized byacute exacerbation and remission phases. Immune system has a role in the pathophysiology of schizophrenia. High mobility group box-1 (HMGB-1) is a macrophage secreted protein activating immune cells to produce cytokines. The aim...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Society of Medical Biochemists of Serbia, Belgrade
2021-01-01
|
Series: | Journal of Medical Biochemistry |
Subjects: | |
Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2021/1452-82582103295Y.pdf |
id |
doaj-b4ae4e2fe092440687455dbc8c4e82fb |
---|---|
record_format |
Article |
spelling |
doaj-b4ae4e2fe092440687455dbc8c4e82fb2021-07-20T07:25:36ZengSociety of Medical Biochemists of Serbia, BelgradeJournal of Medical Biochemistry1452-82581452-82662021-01-0140329530110.5937/jomb0-281081452-82582103295YHigh mobility group box-1 levels in schizophrenia: Potential biomarker of remission phaseYilmaz Nuryil0Yelboga Zekeriya1Yilmaz Yavuz2Demirpence Ozlem3Cumhuriyet University, Faculty of Medicine, Department of Psychiatry, Sivas, TurkeyCumhuriyet University, Faculty of Medicine, Department of Psychiatry, Sivas, TurkeyCumhuriyet University, Faculty of Medicine, Department of Psychiatry, Sivas, TurkeyCumhuriyet University, Faculty of Medicine, Department of Biochemistry, Sivas, TurkeyBackground: Schizophrenia is a chronic mental disorder, characterized byacute exacerbation and remission phases. Immune system has a role in the pathophysiology of schizophrenia. High mobility group box-1 (HMGB-1) is a macrophage secreted protein activating immune cells to produce cytokines. The aim of this study was to evaluate HMGB-1 levels among patients with schizophrenia both in acute exacerbation and remission phases. Methods: Consecutive schizophrenia patients in acute exacerbation and remission phases were enrolled and compared with each other and with age-sex matched healthy subjects. Patients were assessed with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Scale (CGI). Results: Mean HMGB-1 levels were not significantly different in acute exacerbation phase versus remission phase schizophrenia patients (2.139±0.564 g/L vs. 2.326± 0.471 g/L, p=0.335) and both were individually higher than the control group (1.791±0.444 g/L, p=0.05 for acute exacerbation vs control, p=0.002 for remission vs control). In remission phase schizophrenic patients, HMGB-1 levels were positively correlated with Scale For The Assessment of Positive Symptoms (r=0.447, p=0.015) and BPRS (r=0.397, p=0.033) scores and HMGB-1 levels were independently associated with BPRS. Conclusions: Serum HMGB-1 levels were shown to be increased in patients with schizophrenia patients irrespective of phase, there were no differences between patients in acute exacerbation and remission phase in terms of biomarker and HMGB-1 levels were related to symptom severity according to psychiatric scales among patients in remission phase of schizophrenia.https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2021/1452-82582103295Y.pdfschizophreniahmgb-1remission and acute exacerbation phase |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yilmaz Nuryil Yelboga Zekeriya Yilmaz Yavuz Demirpence Ozlem |
spellingShingle |
Yilmaz Nuryil Yelboga Zekeriya Yilmaz Yavuz Demirpence Ozlem High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase Journal of Medical Biochemistry schizophrenia hmgb-1 remission and acute exacerbation phase |
author_facet |
Yilmaz Nuryil Yelboga Zekeriya Yilmaz Yavuz Demirpence Ozlem |
author_sort |
Yilmaz Nuryil |
title |
High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase |
title_short |
High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase |
title_full |
High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase |
title_fullStr |
High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase |
title_full_unstemmed |
High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase |
title_sort |
high mobility group box-1 levels in schizophrenia: potential biomarker of remission phase |
publisher |
Society of Medical Biochemists of Serbia, Belgrade |
series |
Journal of Medical Biochemistry |
issn |
1452-8258 1452-8266 |
publishDate |
2021-01-01 |
description |
Background: Schizophrenia is a chronic mental disorder, characterized byacute exacerbation and remission phases. Immune system has a role in the pathophysiology of schizophrenia. High mobility group box-1 (HMGB-1) is a macrophage secreted protein activating immune cells to produce cytokines. The aim of this study was to evaluate HMGB-1 levels among patients with schizophrenia both in acute exacerbation and remission phases. Methods: Consecutive schizophrenia patients in acute exacerbation and remission phases were enrolled and compared with each other and with age-sex matched healthy subjects. Patients were assessed with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Scale (CGI). Results: Mean HMGB-1 levels were not significantly different in acute exacerbation phase versus remission phase schizophrenia patients (2.139±0.564 g/L vs. 2.326± 0.471 g/L, p=0.335) and both were individually higher than the control group (1.791±0.444 g/L, p=0.05 for acute exacerbation vs control, p=0.002 for remission vs control). In remission phase schizophrenic patients, HMGB-1 levels were positively correlated with Scale For The Assessment of Positive Symptoms (r=0.447, p=0.015) and BPRS (r=0.397, p=0.033) scores and HMGB-1 levels were independently associated with BPRS. Conclusions: Serum HMGB-1 levels were shown to be increased in patients with schizophrenia patients irrespective of phase, there were no differences between patients in acute exacerbation and remission phase in terms of biomarker and HMGB-1 levels were related to symptom severity according to psychiatric scales among patients in remission phase of schizophrenia. |
topic |
schizophrenia hmgb-1 remission and acute exacerbation phase |
url |
https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2021/1452-82582103295Y.pdf |
work_keys_str_mv |
AT yilmaznuryil highmobilitygroupbox1levelsinschizophreniapotentialbiomarkerofremissionphase AT yelbogazekeriya highmobilitygroupbox1levelsinschizophreniapotentialbiomarkerofremissionphase AT yilmazyavuz highmobilitygroupbox1levelsinschizophreniapotentialbiomarkerofremissionphase AT demirpenceozlem highmobilitygroupbox1levelsinschizophreniapotentialbiomarkerofremissionphase |
_version_ |
1721294101426470912 |